Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Fallopian Tube Neoplasms 4Brenner Tumor 4Colorectal Neoplasms 3Colonic Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Virus Diseases 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Tongue Neoplasms 1Stroke 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Lymphoid Interstitial Pneumonia 1Liver Cirrhosis 1Kidney Failure, Chronic 1Hepatitis, Viral, Human 1Hepatitis C 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Endometrial Neoplasms 1

Interventions

hepatitis C immune globulin, human 1Immunoglobulin G 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Hepatitis, Viral, Human × Immunoglobulin G × Clear all
NCT01804829 2017-03-15

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Biotest Pharmaceuticals Corporation

Phase 3 Completed
80 enrolled
Gastrointestinal

Hepatitis, Viral, Human, Hepatitis C, Carcinoma, Hepatocellular, Liver Cirrhosis, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡